Navigation Links
Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
Date:9/30/2008

CRANBURY, N.J., Sept. 30 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN) will discuss the fourth quarter and year end financial results for the fiscal year ended June 30, 2008 and provide an update on corporate developments during a conference call and webcast on September 30, 2008 at 11:15 a.m. ET.

Conference Call and Webcast Access Information

-- Q4-Fiscal Year 2008 Conference September 30, 2008 at

Call - Live 11:15 a.m. ET

Domestic Dial-In Number 1-888-263-2958

International Dial-In Number 1-913-312-6664

-- Q4-Fiscal Year 2008 Conference September 30 - October 7, 2008

Call - Replay

Domestic Dial-In Number 1-888-203-1112

International Dial-In Number 1-719-457-0820

Replay Passcode: 6671824

-- Webcast Live and Replay Access http://www.palatin.com

The webcast and replay can be accessed by logging on to the "Investor Center-Webcasts" section of Palatin's website at http://www.palatin.com.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the development of proprietary peptide, peptide mimetic and small molecule compounds with a focus on melanocortin and natriuretic peptide receptor systems. The melanocortin system is involved in a large and diverse number of physiologic functions, and therapeutic agents modulating this system may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, ischemia and reperfusion injury, hemorrhagic shock and inflammation-related diseases. The natriuretic peptide receptor system has numerous cardiovascular functions, and therapeutic agents modulating this system may be useful in treatment of heart failure, hypertension and other cardiovascular diseases. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
3. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
4. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
5. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
6. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
7. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
8. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
9. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
10. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
11. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... While things have been quiet for ... company and provide a new outlook for the future. As a continued effort ... management with the retirement of Mr. Siegel as CEO. With the new adjustments in ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... digital pathology, today announced their digital pathology technology has the potential to eliminate ... five medical centers in The Netherlands as part of the 2017 ISBI ...
(Date:4/27/2017)... ... April 27, 2017 , ... During the course ... how testing for 1,25-Dihydroxyvitamin D can enhance clinical practice. Participants will learn the ... dihydroxyvitamin D. , Dr. Gregory Plotnikoff, senior consultant with Minnesota Personalized Medicine, will ...
(Date:4/27/2017)... ... 27, 2017 , ... The Council for Agricultural Science and ... Lusk, a consummate communicator who promotes agricultural science and technology in the public ... explains how innovation and growth in agriculture are critical for food security and ...
Breaking Biology Technology:
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
Breaking Biology News(10 mins):